Dermavant Submits NDA to the US FDA for Tapinarof Cream to Treat Plaque Psoriasis

 Dermavant Submits NDA to the US FDA for Tapinarof Cream to Treat Plaque Psoriasis

Dermavant Submits NDA to FDA for Tapinarof Cream to Treat Plaque Psoriasis

Shots:

  • The submission is based on P-III PSOARING 1 & PSOARING 2 data as well as interim results from PSOARING 3 long-term safety study evaluating the safety and efficacy of tapinarof vs vehicle in patients with plaque psoriasis
  • Results: Improvement in PGA scores of 0 or 1 with a minimum 2-grade improvement from baseline @12 wks., improvement in all 2EPs @ 12 wks., 40% of patients achieved complete disease clearance with continued therapy. Additionally, remittive benefit of 4 mos. was identified following treatment discontinuation
  • Tapinarof is a steroid-free, cosmetically elegant, topical cream for the treatment of PsO and AD

Click here to­ read full press release/ article | Ref: Businesswire | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post